Innovative Approaches to Mucopolysaccharidosis Typ..

created a new article

5 d - Translate

Innovative Approaches to Mucopolysaccharidosis Type I Treatment: From ERT to Gene Therapy | #hurler syndrome treatment market # hurler scheie syndrome market # laronidase biosimilar # mucopolysaccharidosis type 1 treatment # aldurazyme patent expiration # sanofi mucopolysaccharidosis / mps i # mucopolysaccharidosis type i market # mucopolysaccharidosis treatment # hurler scheie syndrome market forcast # mps type 1 treatment

Innovative Approaches to Mucopolysaccharidosis Type I Treatment: From ERT to Gene Therapy

Mucopolysaccharidosis type I (MPS I) is a rare inherited disorder caused by the deficiency of the enzyme alpha-L-iduronidase. This deficiency leads to the accumulation of glycosaminoglycans (GAGs), causing progressive organ damage and developmental delays.

Comment

5 d - Translate

Innovative Approaches to Mucopolysaccharidosis Type I Treatment: From ERT to Gene Therapy

Language